outlined in the ICH E5 guideline titled “Ethnic Factors in the Acceptability of Foreign Clinical Data”. Key takeaways include:

• Ethnic factors (intrinsic and extrinsic) can influence drug response
• Foreign clinical data can be acceptable with a bridging justification or study
• Bridging studies can be clinical, PK-based, or PD-based, depending on risk
• Full duplication of Phase 3 is not always necessary

ICH E5 remains the cornerstone for global drug development strategies involving bridging studies.

Types of Bridging Studies

1. Pharmacokinetic Bridging Study

This is the most common type. It compares the absorption, metabolism, distribution, and excretion (ADME) of the drug between local and foreign populations.

2. Dose-Finding Bridging Study

Used when the optimal dose is unclear or may differ due to body weight, diet, genetic polymorphisms, or comorbidities.

3. Confirmatory Efficacy and Safety Bridging Study

Used when PK similarity is not sufficient, or if previous data showed variability in treatment effect across populations.

4. Observational or Real-World Bridging Study

Less common, but sometimes used post-approval to validate real-world performance in the local healthcare setting.

When Are Bridging Studies Required?

Several scenarios prompt the need for a bridging study as part of the Phase 3 program:

• Lack of local subjects in the global Phase 3 dataset
• Ethnic variability in drug metabolism (e.g., CYP450 polymorphisms)
• Different comorbidity profiles or healthcare systems
• Regulatory requirements from agencies such as CDSCO (India), PMDA (Japan), NMPA (China)

Early discussion with national regulators helps clarify whether a bridging study will be necessary.

Regulatory Expectations by Region

• CDSCO (India): Requires local clinical trials or bridging studies unless waived due to serious disease or orphan status
• PMDA (Japan): Demands clear ethnic bridging rationale, including local PK data, under its “Clinical Trial Consultation” framework
• NMPA (China): Historically required local trials; now more open to ICH E5/E17-aligned bridging with PK/PD data
• FDA and EMA: Accept foreign data but encourage demographic subgroup analyses for ethnic minorities

As global harmonization improves, the role of bridging studies continues to evolve.

Designing a Bridging Study: Key Considerations

• Population: Must reflect the target country’s ethnic or regional characteristics
• Sample size: Often smaller than full Phase 3 trials—based on variability and endpoint type
• Endpoints: Should include both efficacy (when required) and PK/PD/safety markers
• Design: May be open-label, single-arm, or randomized depending on the question

The goal is to generate sufficient evidence to bridge the gap between foreign data and local applicability.

Statistical Analysis in Bridging Studies

Statistical methods are used to determine whether the local population responds similarly to the reference population. Key methods include:

• Equivalence testing of PK parameters (Cmax, AUC)
• Non-inferiority testing for efficacy in confirmatory trials
• Subgroup analysis to compare demographic strata

Agencies often expect side-by-side forest plots and meta-analytic summaries to support extrapolation.

Case Example: Bridging Study in Type 2 Diabetes in Japan

A multinational company conducted a global Phase 3 trial for a GLP-1 receptor agonist but lacked sufficient Japanese participants. The PMDA required a local PK bridging study comparing drug levels and tolerability between Japanese and Western subjects.

The study showed similar PK and safety profiles, and the drug was approved in Japan without the need for a full local efficacy trial.

Bridging in the Era of Multi-Regional Clinical Trials (MRCTs)

ICH E17 promotes integrated multi-regional trials that pre-empt the need for bridging by including global populations from the start. However, if certain populations are underrepresented, bridging studies may still be needed post-hoc.

Best practice is to strategically select trial sites in key markets during Phase 3 to minimize the need for separate bridging programs.

Best Practices for Sponsors

• Start early: Discuss bridging needs with regulators during protocol planning
• Use population PK modeling: Supports dose justification across regions
• Align endpoints: Match endpoints to the global Phase 3 for easier comparison
• Ensure data quality: Apply GCP and harmonized data collection across regions

Well-executed bridging studies enable faster access to life-saving therapies worldwide.

Final Thoughts

Bridging studies are an essential component of global Phase 3 strategies. They ensure that clinical data can be applied to diverse populations and meet the specific requirements of local regulators. By understanding how and when to design a bridging study, sponsors can streamline development, support global filings, and enhance access.

At ClinicalStudies.in, learning the role of bridging studies prepares you for global clinical operations, regulatory strategy, and medical affairs in multinational trial environments.